EcoDrugPlus

Transient Receptor Potential Cation Channel, Subfamily A, Member 1a

Ensembl ID : ENSOMYG00000011784
Gene Symbol: TRPA1A
1 Cross references
149 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily A, Member 1a

Ensembl ID : ENSOMYG00000043906
Gene Symbol: TRPA1A
1 Cross references
149 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily A, Member 1b

Ensembl ID : ENSOMYG00000017696
Gene Symbol: TRPA1B
1 Cross references
194 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily A, Member 1b

Ensembl ID : ENSOMYG00000030566
Gene Symbol: TRPA1B
1 Cross references
193 Possible Orthologues:

Transthyretin (Prealbumin, Amyloidosis Type I)

Ensembl ID : ENSOMYG00000032166
Gene Symbol: TTR
1 Cross references
178 Possible Orthologues:

Tryptophan Hydroxylase 1 (Tryptophan 5-Monooxygenase) A

Ensembl ID : ENSOMYG00000000567
Gene Symbol: TPH1A
1 Cross references
158 Possible Orthologues:

Tubulin Beta 3 Class Iii

Ensembl ID : ENSOMYG00000026304
Gene Symbol: TUBB3
1 Cross references
134 Possible Orthologues:

Tubulin Beta 3 Class Iii

Ensembl ID : ENSOMYG00000041036
Gene Symbol: TUBB3
1 Cross references
133 Possible Orthologues:

Tubulin, Alpha 7 Like

Ensembl ID : ENSOMYG00000056700
Gene Symbol: TUBA7L
1 Cross references
310 Possible Orthologues:

Tubulin, Alpha 7 Like

Ensembl ID : ENSOMYG00000044590
Gene Symbol: TUBA7L
1 Cross references
312 Possible Orthologues:

Tubulin, Alpha 8 Like 2

Ensembl ID : ENSOMYG00000007598
Gene Symbol: TUBA8L2
1 Cross references
194 Possible Orthologues:

Tubulin, Alpha 8 Like 2

Ensembl ID : ENSOMYG00000009711
Gene Symbol: TUBA8L2
1 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).